News

In the study, the major adverse cardiac events (MACE) free survival rate in patients treated with the Genous Stent was 80.6% after one year. The single-center study investigated

Established in San Francisco’s Mission Bay life sciences hub, the new Innovation Center comprises of scientists who are working for Bayer‘s hematology research program which is focused on

Under the agreement, Cephalon will use Celator’s proprietary technology in an ongoing drug development and life-cycle management program at Cephalon. Celator Pharma CEO Scott Jackson said they are

Regorafenib is an oral multi-kinase inhibitor, which targets angiogenic (VEGFR, TIE-2), stromal (PDGFR-ß) and oncogenic (RAF, RET and KIT) receptor tyrosine kinases. The randomised, double-blind, placebo-controlled, multi-centre, cross-over

A pivotal phase III trial of XL184 in patients medullary thyroid cancer (MTC) in currently being conducted. Exelixis expects to release top-line phase III results in the first-half

In the single dose, single-site, randomised, placebo- and active-controlled study, 135 subjects received Vyvanse 20mg, 50mg, 70mg, placebo or the active comparator (armodafinil 250mg (NUVIGIL)). On the primary

Reportedly, the company has recruited first patient in September 2010. In the trial, the patients are expected to receive immunization over a period of six months, with the

With this, Mannatech will now hold 12 patents for technology related to Ambrotose AO in Australia, Mexico, New Zealand, Singapore, South Africa and South Korea. Mannatech co-CEO and

GSK and Galapagos signed the arthritis alliance in June 2006 for the discovery and development of disease-modifying drugs for GSK’s global R&D organization. In the trial, GLPG0555 was